Credit Suisse Group Reiterates GBX 1,600 Price Target for GlaxoSmithKline (GSK)
Other equities research analysts also recently issued research reports about the stock. Shore Capital reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Tuesday, August 7th. Berenberg Bank reaffirmed a buy rating and issued a GBX 1,790 ($23.39) price objective on shares of GlaxoSmithKline in a report on Thursday, August 23rd. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a report on Tuesday, August 21st. Jefferies Financial Group set a GBX 1,775 ($23.19) price objective on shares of GlaxoSmithKline and gave the stock a buy rating in a report on Thursday, August 16th. Finally, Liberum Capital reaffirmed a buy rating on shares of GlaxoSmithKline in a report on Tuesday, August 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of Hold and an average target price of GBX 1,512.99 ($19.77).
GSK stock opened at GBX 1,437.40 ($18.78) on Tuesday. GlaxoSmithKline has a fifty-two week low of GBX 1,235.20 ($16.14) and a fifty-two week high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Recommended Story: How accurate is the Rule of 72?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.